Stevanato Group Spa (STVN) has released an update.
Stevanato Group S.p.A., a major player in pharmaceutical and life sciences solutions, has successfully closed an upsized public offering, raising approximately $379.7 million through the sale of 14,605,000 ordinary shares, with both the company and a major shareholder selling equal shares. The company aims to utilize the proceeds for general corporate purposes, such as ongoing investments and working capital needs, while not benefiting from the shareholder’s offering. Leading financial institutions, including Morgan Stanley and William Blair, managed the offering process.
For further insights into STVN stock, check out TipRanks’ Stock Analysis page.
